DURHAM, N.C.– BioSkryb Genomics, a pioneer in comprehensive single-cell multi-omic research solutions, has appointed Suresh Pisharody as its new CEO. Mr. Pisharody brings a wealth of experience in building life sciences tools and diagnostic businesses globally. His expertise in developing and implementing business strategies to enter new markets will be instrumental as the company aims to establish itself as a leader in the rapidly expanding genomics and precision medicine industries.
Mr. Pisharody is a seasoned executive with a proven track record in product management, strategy, commercialization, and marketing of some of the most successful products in the genomics and molecular diagnostics industries. He built the foundation of his success during his tenure at Illumina, where he led the sequencing product management organization and introduced innovative, next-generation sequencing systems. These products, such as the Illumina Genome Analyzer, MiSeq, and HiSeq™ Sequencing systems, helped grow NGS sequencing into a multibillion-dollar market. Later, he assumed leadership roles at leading NGS-based diagnostics companies, such as Personalis and Guardant Health, as well as on the executive team in the Clinical Sequencing Division at Thermo Fisher. Most recently, he served as an Entrepreneur in Residence at Illumina Ventures, where he focused on integrating businesses in the single-cell and spatial genomics space.
“The team at BioSkryb has developed groundbreaking solutions that solve the traditional challenges associated with genome-scale single-cell analysis, ushering in a new era of multiomic analysis and single cell genomics,” said Mr. Pisharody. “I am thrilled to be on board to help drive BioSkryb forward, on our mission of advancing the development of more precise diagnostics and treatments for patients.”
BioSkryb Genomics is a rapidly growing organization that is transforming single cell molecular discovery and analysis. Through its products and services, scientists and clinicians can gain an unprecedented view of the genome, transcriptome, and proteome within a single cell to better understand the drivers, mechanisms, and management of complex disease.
“Suresh is an impressive leader with a unique combination of technical, commercial, and executive management skills that were developed and proven at some of the most well-known companies in the genomics space,” said David Michael, Managing Partner at Anzu Partners, and Chairman of the Board at BioSkryb. “I am delighted to welcome Suresh during this transformative time for the company, and know he has the skills and experience to bring BioSkryb’s differentiated technology to the forefront of this booming industry.”
Jay West, BioSkryb’s Founding CEO will transition into a new role as Chief Technology Officer and will remain an important member of the BioSkryb Board of Directors and its leadership team.
“I am thrilled to welcome Suresh to the BioSkryb leadership team and partner with him to continue to advance the BioSkryb mission and achievement of our growth objectives.” said West. “Our vision to eradicate threats to human health is within our grasp. As CTO, I’m excited to continue our work on delivering the most extraordinary view and data quality of the multiomic ecosystem within a single cell at a throughput that accelerates the impact on the understanding, treatment, and management of disease.”
